MJA
MJA

Clenbuterol toxicity: a NSW Poisons Information Centre experience

Med J Aust 2014; 200 (4): 219-221. || doi: 10.5694/mja13.10982

Summary

Objective: To describe the epidemiology and toxicity of clenbuterol in exposures reported to the NSW Poisons Information Centre (NSWPIC).

Design and setting: Retrospective observational study analysing data from all calls about clenbuterol exposure recorded in the NSWPIC database from 1 January 2004 to 31 December 2012. The NSWPIC coversthe Australian jurisdictions New South Wales, Tasmania and the Australian Capital Territory 24 hours a day and provides after-hours cover for the rest of Australia for 7 nights each fortnight.

Main outcome measures: Total number of exposures, source of call (hospital, health care worker, member of the public), time from exposure to call, reasons for drug use, clinical features and advice given.

Results: Callers reported 63 exposures to clenbuterol, with a dramatic increase from three in 2008 to 27 in 2012. Of the 63 calls, 35 were from hospital, two from paramedics, one from general practice and 21 direct from the public. At least 53 patients (84%) required hospitalisation. The commonest reasons for use were bodybuilding and slimming. The most common features were tachycardia (24 patients), gastrointestinal disturbance (16) and tremor (11). Exposure was also associated with cardiotoxicity including one cardiac arrest in a 21-year-old man.

Conclusion: Although a well recognised doping issue among elite athletes, clenbuterol use has spread out into the general public, especially during 2012, and should be considered in patients using bodybuilding or slimming products who present with protracted sympathomimetic features. The potential for misuse of this substance requires reconsideration of its current poison schedule registration and its availability.

Please login with your free MJA account to view this article in full

  • Jonathan Brett1
  • Andrew H Dawson2
  • Jared A Brown2

  • 1 Drug Health, Royal Prince Alfred Hospital, Sydney, NSW.
  • 2 NSW Poisons Information Centre, The Children's Hospital at Westmead, Sydney, NSW.


Competing interests:

No relevant disclosures.

  • 1. Couet W, Girault J, Reigner BG, et al. Steady-state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation. Int J Clin Pharmacol Ther Toxicol 1989; 27: 467-472.
  • 2. ComLaw. Poisons Standard 2012 — F2012L01200. Schedule 1 — Standard for the Uniform Scheduling of Medicines and Poisons No. 3. Commonwealth of Australia, 2012. http://www.comlaw.gov.au/Details/F2012L01200 (accessed Aug 2013).
  • 3. Mitchell GA, Dunnavan G. Illegal use of beta-adrenergic agonists in the United States. J Anim Sci 1998; 76: 208-211.
  • 4. Barbosa J, Cruz C, Martins J, et al. Food poisoning by clenbuterol in Portugal. Food Addit Contam 2005; 22: 563-566.
  • 5. Salleras L, Dominguez A, Mata E, et al. Epidemiologic study of an outbreak of clenbuterol poisoning in Catalonia, Spain. Public Health Rep 1995; 110: 338-342.
  • 6. Kuiper HA, Noordam MY, van Dooren-Flipsen MM, et al. Illegal use of beta-adrenergic agonists: European Community. J Anim Sci 1998; 76: 195-207.
  • 7. Hoffman RS, Kirrane BM, Marcus SM; Clembuterol Study Investigators. A descriptive study of an outbreak of clenbuterol-containing heroin. Ann Emerg Med 2008; 52: 548-553.
  • 8. Daubert GP, Mabasa VH, Leung VW, Aaron C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol 2007; 3: 56-60.
  • 9. Kierzkowska B, Stan´czyk J, Kasprzak JD. Myocardial infarction in a 17-year-old body builder using clenbuterol. Circ J 2005; 69: 1144-1146.
  • 10. Goldstein DR, Dobbs T, Krull B, Plumb VJ. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. South Med J 1998; 91: 780-784.
  • 11. Schechter E, Hoffman RS, Stajic M, et al. Pulmonary edema and respiratory failure associated with clenbuterol exposure. Am J Emerg Med 2007; 25: 735.e1-e3.
  • 12. Chan TY. Health hazards due to clenbuterol residues in food. J Toxicol Clin Toxicol 1999; 37: 517-519.
  • 13. World Anti-Doping Agency. WADA statement on clenbuterol 2011. http://www.wada-ama.org/en/media-center/archives/articles/wada-statement-on-clenbuterol (accessed Jun 2013).
  • 14. Spiller HA, James KJ, Scholzen S, Borys DJ. A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst Abus 2013; 34: 306-312.
  • 15. Guest K. Clenbuterol: the new weight loss wonder drug gripping planet zero. The Independent 2014; 4 Feb. http://www.independent.co.uk/life-style/health-and-families/health-news/clenbuterol-the-new-weightloss-wonder-drug-gripping-planet-zero-441059.html (accessed Feb 2014).
  • 16. Pulce C, Saviuc P, Pineau X, et al. Clenbuterol: retrospective study of cases from the French poison and toxicovigilance centres between 2000 and 2008 [abstract]. Clin Toxicol 2011; 49: 215.
  • 17. Lust EB, Barthold C, Wichman TO, et al. Human health hazards of veterinary medications: information for emergency departments. J Emerg Med 2011; 40: 198-207.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article